Remicade® (Infliximab) Referral Form



10750 W. Howard Ave Greenfield, WI 53228 Phone: (414) 460-3195 Fax: (414) 763-0063 www.gtinfusions.com

Patient Information				
Patient Name:			Patient DOB:	
Referral Status				
☐ New Referral ☐ Restart		☐ Medication/Order Cha	inge	D/C Infusions
Diagnosis and ICD 10 Code				
☐ Moderate to Severe Ulcerative Colitis ICD 10 Code: K5				
☐ Moderate to Severe Crohn's Disease ICD 10 Code: K50				
Rheumatoid Arthritis ICD 10 Code: M06.9				
Ankylosing Spondylitis ICD 10 Code: M4			ode: M45.9	
Psoriatic Arthritis ICD 10 Code: L40.52				
Plaque Psoriasis ICD 10 Code: K50.90				
Other Diagnosis: ICD 10 Code:				
Required Documentation				
Patient demographics		☐ Clinical/Progress notes supporting primary diagnosis		
Copy of patient insurance card(s) – fr	ont & back	Labs and tests supporting primary diagnosis		gnosis
Tried and Failed therapies	☐ Tried and Failed therapies ☐ TB and Hepatitis B test resu		st results: HBsAg	Total HebB Core Antibody
Medication Orders				
Induction/Maintenance Dosing Remicade®: 3mg/kg IV at week 0, 2, 6, then every 8 weeks thereafter 5mg/kg IV at week 0, 2, 6, then every 8 weeks thereafter Maintenance Dose Remicade®: 3 mg/kg IV every 8 weeks 5mg/kg IV every 8 weeks				
Patient Weight = kg Notes (Additional Info)				
Premedication, adverse and anaphylactic reactions and post infusion will be treated per Gamma Therapeutic Center protocol.				
Prescriber Information				
Prescriber Name:			NPI #:	
Office Contact: Office Phone:		Office Fax:		
Prescriber Signature:			Date:	(Order is valid for one year)
My signature for this prescription also confirms that the treatment(s) indicated on this referral is/are medically necessary. I authorize Gamma Therapeutic Center and its representatives to act as an agent of mine to initiate and execute the patient's insurance prior authorization process and to provide infusion-related nursing services and supplies in conjunction with the therapy prescribed above.				
Notify patient we will contact the patient and schedule their treatment once our benefit investigation and any prior authorizations have been completed.				

Confidentiality statement: This message is intended only for the individual or institution to which it is addressed. This may contain information, which is confidential, privileged, and/or proprietary. This information may be exempt from disclosure under applicable laws including but not limited to HIPAA. If you are not the intended recipient, please note you are strictly prohibited from distributing, copying, or disseminating this information. If you received this information in error, please notify the sender noted above and destroy all transmitted material.